# Nonsteroidal Anti‐Inflammatory Drugs as Modulators of Cation Channels: Fenamates Repurposing in Channelopathies

**Authors:** Paola Laghetti, Concetta Altamura, Simone Dell’Atti, Jean‐François Desaphy, Ilaria Saltarella

PMC · DOI: 10.1002/cmdc.202500301 · Chemmedchem · 2025-09-14

## TL;DR

This paper reviews how fenamates, a type of anti-inflammatory drug, can modulate cation channels and may be repurposed to treat various channel-related disorders.

## Contribution

The paper highlights the novel potential of fenamates as modulators of cation channels for therapeutic repurposing.

## Key findings

- Fenamates differentially modulate cationic ion channels, offering new therapeutic opportunities.
- Preclinical and clinical studies suggest fenamates could be repurposed for treating channelopathies and related disorders.
- Fenamates show promise in managing conditions like chronic pain, epilepsy, and cardiac arrhythmias.

## Abstract

Cationic ion channels are transmembrane proteins that regulate the flux of cations (potassium, sodium, and calcium) across cell membrane, playing a pivotal role in many cellular functions. Disruptions of their activity can lead to the so‐called genetic or acquired channelopathies, a heterogeneous group of diseases that affect multiple human systems. Fenamates, a class of nonsteroidal anti‐inflammatory drugs, has recently emerged as modulators of cationic ion channels highlighting the possibility of their repurposing for the treatment ion channel‐related disorders, such as channelopathies, chronic pain, epilepsy, cardiac arrhythmias, and cancers. In this review, the ability of fenamates (i.e. niflumic, flufenamic, mefenamic, meclofenamic, and tolfenamic acids) to differentially modulate the activity of cationic ion channels is described. Overall, preclinical and clinical studies suggest that fenamates represent a promising class of compounds for drug repurposing and for the development of new molecules, offering novel therapeutic opportunities for patients affected by ion channel‐related disorders.

Beyond their established role as nonsteroidal anti‐inflammatory drugs (NSAIDs), fenamates (niflumic, flufenamic, mefenamic, meclofenamic, and tolfenamic acids) have recently been identified as modulators of cationic ion channels. This review highlights their differential effects on ion channel activity and explores their potential for repurposing in the treatment of channelopathies, chronic pain, epilepsy, cardiac arrhythmias, and cancer.© 2025 WILEY‐VCH GmbH

## Linked entities

- **Diseases:** epilepsy (MONDO:0005027)

## Full-text entities

- **Diseases:** chronic pain (MESH:D059350), cancers (MESH:D009369), CHANNELOPATHIES (MESH:D053447), ion channel-related disorders (MESH:D019973), epilepsy (MESH:D004827), genetic (MESH:D030342), cardiac arrhythmias (MESH:D001145)
- **Chemicals:** sodium (MESH:D012964), tolfenamic acids (MESH:C009500), FENAMATES (MESH:D054361), calcium (MESH:D002118), flufenamic (-), potassium (MESH:D011188)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12530847/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12530847/full.md

## References

154 references — full list in the complete paper: https://tomesphere.com/paper/PMC12530847/full.md

---
Source: https://tomesphere.com/paper/PMC12530847